"epidermal glands called elaiophores" trang 8 - tải miễn phí từ tailieuXANH
DsRNA silencing of an R2R3-MYB transcription factor affects flower cell shape in a Dendrobium hybrid

DsRNA silencing of an R2R3-MYB transcription factor affects flower cell shape in a Dendrobium hybrid
14    41    0
A phase II study of Osimertinib for patients with radiotherapy-naïve CNS metastasis of non-small cell lung cancer: Treatment rationale and protocol design of the OCEAN study (LOGIK 1603/WJOG 9116L)

A phase II study of Osimertinib for patients with radiotherapy-naïve CNS metastasis of non-small cell lung cancer: Treatment rationale and protocol design of the OCEAN study (LOGIK 1603/WJOG 9116L)
6    71    0
Anti-HER2 induced myeloid cell alterations correspond with increasing vascular maturation in a murine model of HER2+ breast cancer

Anti-HER2 induced myeloid cell alterations correspond with increasing vascular maturation in a murine model of HER2+ breast cancer
13    48    0
Sensitive detection methods are key to identify secondary EGFR c.2369C>T p.(Thr790Met) in non-small cell lung cancer tissue samples

Sensitive detection methods are key to identify secondary EGFR c.2369C>T p.(Thr790Met) in non-small cell lung cancer tissue samples
11    60    0
Prognostic value of TP53 concurrent mutations for EGFR- TKIs and ALK-TKIs based targeted therapy in advanced nonsmall cell lung cancer: A meta-analysis

Prognostic value of TP53 concurrent mutations for EGFR- TKIs and ALK-TKIs based targeted therapy in advanced nonsmall cell lung cancer: A meta-analysis
16    60    0
EGFR mutation testing and treatment decisions in patients progressing on firstor second-generation epidermal growth factor receptor tyrosine kinase inhibitors

EGFR mutation testing and treatment decisions in patients progressing on firstor second-generation epidermal growth factor receptor tyrosine kinase inhibitors
13    76    0
Clinical performance evaluation of the Idylla™ EGFR Mutation Test on formalinfixed paraffin-embedded tissue of nonsmall cell lung cancer

Clinical performance evaluation of the Idylla™ EGFR Mutation Test on formalinfixed paraffin-embedded tissue of nonsmall cell lung cancer
10    54    0
MiR-762 activation confers acquired resistance to gefitinib in non-small cell lung cancer

MiR-762 activation confers acquired resistance to gefitinib in non-small cell lung cancer
14    83    0
Young-onset gastric cancer and Epstein– Barr Virus (EBV) – a major player in the pathogenesis?

Young-onset gastric cancer and Epstein– Barr Virus (EBV) – a major player in the pathogenesis?
7    72    0
Systemic treatment of hormone receptor positive, human epidermal growth factor 2 negative metastatic breast cancer: Retrospective analysis from Leeds Cancer Centre

Systemic treatment of hormone receptor positive, human epidermal growth factor 2 negative metastatic breast cancer: Retrospective analysis from Leeds Cancer Centre
12    71    0
Emergence of RAS mutations in patients with metastatic colorectal cancer receiving cetuximab-based treatment: A study protocol

Emergence of RAS mutations in patients with metastatic colorectal cancer receiving cetuximab-based treatment: A study protocol
7    48    0
Impact of molecular subtypes on the prediction of distant recurrence in estrogen receptor (ER) positive, human epidermal growth factor receptor 2 (HER2) negative breast cancer upon five years of endocrine therapy

Impact of molecular subtypes on the prediction of distant recurrence in estrogen receptor (ER) positive, human epidermal growth factor receptor 2 (HER2) negative breast cancer upon five years of endocrine therapy
9    55    0
Comparative survival benefit of currently licensed second or third line treatments for epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) negative advanced or metastatic non-small cell lung cancer: A systematic review and secondary analysis of trials

Comparative survival benefit of currently licensed second or third line treatments for epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) negative advanced or metastatic non-small cell lung cancer: A systematic review and secondary analysis of trials
17    48    0
Two open-label, single arm, non-randomized phase II studies of irinotecan for the treatment of metastatic breast cancer in patients with increased copy number of the topoisomerase I gene

Two open-label, single arm, non-randomized phase II studies of irinotecan for the treatment of metastatic breast cancer in patients with increased copy number of the topoisomerase I gene
5    57    0
MiR-890 inhibits proliferation and invasion and induces apoptosis in triple-negative breast cancer cells by targeting CD147

MiR-890 inhibits proliferation and invasion and induces apoptosis in triple-negative breast cancer cells by targeting CD147
11    51    0
First-line single-agent panitumumab in frail elderly patients with wild-type RAS unresectable colorectal cancer: A phase II study protocol OGSG 1602

First-line single-agent panitumumab in frail elderly patients with wild-type RAS unresectable colorectal cancer: A phase II study protocol OGSG 1602
5    47    0
Clinical outcome of treatment of metastatic non-small cell lung cancer in patients harboring uncommon EGFR mutation

Clinical outcome of treatment of metastatic non-small cell lung cancer in patients harboring uncommon EGFR mutation
9    68    0
Afatinib helped overcome subsequent resistance to osimertinib in a patient with NSCLC having leptomeningeal metastasis baring acquired EGFR L718Q mutation: A case report

Afatinib helped overcome subsequent resistance to osimertinib in a patient with NSCLC having leptomeningeal metastasis baring acquired EGFR L718Q mutation: A case report
6    64    0
Discordance in HER2 status between primary gastric adenocarcinoma tumors and cells from the corresponding malignant effusions

Discordance in HER2 status between primary gastric adenocarcinoma tumors and cells from the corresponding malignant effusions
9    64    1
Combined targeting of HER-2 and HER-3 represents a promising therapeutic strategy in colorectal cancer

Combined targeting of HER-2 and HER-3 represents a promising therapeutic strategy in colorectal cancer
12    57    0
Đã phát hiện trình chặn quảng cáo AdBlock
Trang web này phụ thuộc vào doanh thu từ số lần hiển thị quảng cáo để tồn tại. Vui lòng tắt trình chặn quảng cáo của bạn hoặc tạm dừng tính năng chặn quảng cáo cho trang web này.